PMID- 15176719
OWN - NLM
STAT- MEDLINE
DCOM- 20040820
LR  - 20191108
IS  - 0803-5326 (Print)
IS  - 0803-5326 (Linking)
VI  - 93
IP  - 445
DP  - 2004 May
TI  - The genetic basis for measles vaccine failure.
PG  - 43-6; discussion 46-7
AB  - The US measles epidemics of 1989-1991 included a series of outbreaks resulting 
      from vaccine failure. A series of studies was launched aimed at elucidating the 
      mechanisms of this vaccine failure. A meta-analysis of the literature examining 
      epidemics in vaccinated populations was conducted, which showed that the 
      secondary vaccine failure rate (development of the disease despite an initial or 
      primary vaccine success) is no more than 0.2%. The overwhelming proportion of 
      measles vaccine failure was due to primary vaccine failure (failure to ever 
      generate antibody from antigenic stimulation). This comparison of two 
      geographically distinct communities revealed that 10% of children previously 
      vaccinated against measles lacked antibody on follow-up and that these vaccine 
      failures clustered in families. A study of monozygotic and dizygotic twins 
      revealed a high degree of heritability of measles vaccine antibody level. 
      Subsequent studies found associations with both class I and class II alleles in 
      these population-based studies. In the future, detection of the specific peptides 
      that interact with human leukocyte antigen (HLA) molecules may serve as the basis 
      for improved vaccines and address vaccine failure that results from cold-chain 
      problems, immaturity of the immune system, malnutrition and maternal immunity.
FAU - Jacobson, R M
AU  - Jacobson RM
AD  - Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 
      55905-0001, USA. jacobson.robert@mayo.edu
FAU - Poland, G A
AU  - Poland GA
LA  - eng
GR  - M01 RR-00585/RR/NCRR NIH HHS/United States
GR  - N01 AI 45240/AI/NIAID NIH HHS/United States
GR  - R01 AI33144/AI/NIAID NIH HHS/United States
GR  - R01 AI48793/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Norway
TA  - Acta Paediatr Suppl
JT  - Acta paediatrica (Oslo, Norway : 1992). Supplement
JID - 9315043
RN  - 0 (HLA Antigens)
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Antibody Formation/*genetics
MH  - *Genetic Variation
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Measles/*epidemiology/*genetics/immunology
MH  - Measles Vaccine/*genetics/immunology
MH  - Seroepidemiologic Studies
MH  - Treatment Failure
MH  - United States/epidemiology
RF  - 16
EDAT- 2004/06/05 05:00
MHDA- 2004/08/21 05:00
CRDT- 2004/06/05 05:00
PHST- 2004/06/05 05:00 [pubmed]
PHST- 2004/08/21 05:00 [medline]
PHST- 2004/06/05 05:00 [entrez]
AID - 10.1111/j.1651-2227.2004.tb03055.x [doi]
PST - ppublish
SO  - Acta Paediatr Suppl. 2004 May;93(445):43-6; discussion 46-7. doi: 
      10.1111/j.1651-2227.2004.tb03055.x.